Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib in Relapsed or Refractory Marginal Zone Lymphoma
NCT03144674Phase 2Completed
- Sponsor
- Incyte
- Start
- Dec 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of parsaclisib in marginal zone lymphoma (MZL), sponsored by Incyte. Started Dec 2017; status: completed.
02
Drugs
parsaclisib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03144674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144674.